Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).
Year: 2007
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Todd Alekshun, Christine Mcisaac-Simonelli, Mohamed Kharfan-Dabaja, William Dalton, Benjamin Djulbegovic, Hugo Fernandez, Daniel M. Sullivan, Ernesto Ayala, Teresa L. Field, Dawn Garrett, William E. Janssen, Beth Maddox, Lia Perez, Dawn Kettner, Janelle Perkins, Jyoti Raychaudhuri, Claudio Anasetii, Melissa Alsina
Institution: Moffitt Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2476949936